Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

Autor: Cooke, GS, Andrieux-Meyer, I, Applegate, TL, Atun, R, Burry, JR, Cheinquer, H, Dusheiko, G, Feld, JJ, Gore, C, Griswold, MG, Hamid, S, Hellard, ME, Hou, JL, Howell, J, Jia, J, Kravchenko, N, Lazarus, JV, Lemoine, M, Lesi, OA, Maistat, L, McMahon, BJ, Razavi, H, Roberts, TR, Simmons, B, Sonderup, MW, Spearman, CW, Taylor, BE, Thomas, DL, Waked, I, Ward, JW, Wiktor, SZ, Abdo, A, Aggarwal, R, Aghemo, A, Al-Judaibi, B, Al Mahtab, M, Altaf, A, Ameen, Z, Asselah, T, Baatarkkhuu, O, Barber, E, Barnes, E, Boulet, P, Burrows, L, Butsashvili, M, Chan, E, Chow, C, Cowie, B, Cunningham, C, De Araujo, A, Diap, G, Dore, G, Doyle, J, Elsayed, M, Fajardo, E, Gane, E, Getehun, A, Goldberg, D, Got, T, Hickman, M, Hill, A, Hutchinson, S, Jones, C, Kamili, S, Khan, A, Lee, A, Lee, TY, Malani, J, Morris, TM, Nayagam, S, Njouom, R, Ocama, P, Pedrana, A, Peeling, R, Reddy, A, Roberts, T, Sacks, J, Sarin, S, Shimakawa, Y, Silva, M, Skala, P, Taylor-Robinson, S, Thompson, A, Thursz, M, Tonganibeia, A, Wallace, J, Ward, J, Wolff, F, Vickerman, P, Yau, J
Přispěvatelé: Wellcome Trust, Medical Research Council (MRC), National Institute for Health Research
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
Economic growth
HIV Infections
Hepacivirus
Innovative financing
Commission
Global Health
Health Services Accessibility
Hepatitis
0302 clinical medicine
Cost of Illness
HEPATOCELLULAR-CARCINOMA
Prevalence
Global health
Medicine
Child
GLOBAL EPIDEMIOLOGY
Incidence
Vaccination
Gastroenterology
Lancet Gastroenterology & Hepatology Commissioners
Middle Aged
Hepatitis B
DISEASE BURDEN
Hepatitis C
Child
Preschool

SPECIAL ADMINISTRATIVE REGION
030220 oncology & carcinogenesis
Female
030211 gastroenterology & hepatology
HEALTH-CARE WORKERS
Viral hepatitis
Life Sciences & Biomedicine
Adult
Hepatitis B virus
medicine.medical_specialty
Adolescent
World Health Organization
B IMMUNIZATION PROGRAM
Communicable Diseases
Young Adult
03 medical and health sciences
DIRECT-ACTING ANTIVIRALS
MINIMUM TARGET PRICES
Humans
Tuberculosis
Disease burden
Science & Technology
Gastroenterology & Hepatology
Hepatology
business.industry
Public health
medicine.disease
INJECTING DRUG-USE
business
Delivery of Health Care
C VIRUS-INFECTION
Zdroj: Lancet Gastroenterology and Hepatology. 4(2)
ISSN: 2468-1253
Popis: Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV and tuberculosis. Highly effective prevention measures and treatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member states. Ambitious targets call for a global reduction in hepatitis-related mortality of 65% and a 90% reduction in new infections by 2030. This Commission draws together a wide range of expertise to appraise the current global situation and to identify priorities globally, regionally, and nationally needed to accelerate progress. We identify 20 heavily burdened countries that account for over 75% of the global burden of viral hepatitis. Key recommendations include a greater focus on national progress towards elimination with support given, if necessary, through innovative financing measures to ensure elimination programmes are fully funded by 2020. In addition to further measures to improve access to vaccination and treatment, greater attention needs to be paid to access to affordable, high-quality diagnostics if testing is to reach the levels needed to achieve elimination goals. Simplified, decentralised models of care removing requirements for specialised prescribing will be required to reach those in need, together with sustained efforts to tackle stigma and discrimination. We identify key examples of the progress that has already been made in many countries throughout the world, demonstrating that sustained and coordinated efforts can be successful in achieving the WHO elimination goals.
Databáze: OpenAIRE